Compare AANJANEYA LIFECARE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS PANACEA BIOTECH DR. DATSONS LABS/
PANACEA BIOTECH
 
P/E (TTM) x -10.9 10.7 - View Chart
P/BV x 0.2 2.3 7.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
PANACEA BIOTECH
Mar-19
DR. DATSONS LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126354 35.5%   
Low Rs31138 22.4%   
Sales per share (Unadj.) Rs133.074.6 178.4%  
Earnings per share (Unadj.) Rs0.26.7 2.3%  
Cash flow per share (Unadj.) Rs6.615.5 42.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.857.2 225.1%  
Shares outstanding (eoy) m31.6661.25 51.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.3 17.8%   
Avg P/E ratio x516.136.8 1,401.9%  
P/CF ratio (eoy) x11.815.9 74.6%  
Price / Book Value ratio x0.64.3 14.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,47715,061 16.4%   
No. of employees `000NA2.3 0.0%   
Total wages/salary Rs m561,471 3.8%   
Avg. sales/employee Rs ThNM1,973.6-  
Avg. wages/employee Rs ThNM635.6-  
Avg. net profit/employee Rs ThNM176.8-  
INCOME DATA
Net Sales Rs m4,2114,567 92.2%  
Other income Rs m7945 175.7%   
Total revenues Rs m4,2894,612 93.0%   
Gross profit Rs m5692,030 28.0%  
Depreciation Rs m204540 37.9%   
Interest Rs m4301,048 41.0%   
Profit before tax Rs m13486 2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m677 7.9%   
Profit after tax Rs m5409 1.2%  
Gross profit margin %13.544.4 30.4%  
Effective tax rate %48.015.9 302.9%   
Net profit margin %0.19.0 1.3%  
BALANCE SHEET DATA
Current assets Rs m6,8522,415 283.8%   
Current liabilities Rs m6,7119,077 73.9%   
Net working cap to sales %3.3-145.9 -2.3%  
Current ratio x1.00.3 383.9%  
Inventory Days Days16165 247.1%  
Debtors Days Days31871 449.1%  
Net fixed assets Rs m3,6738,333 44.1%   
Share capital Rs m31761 516.5%   
"Free" reserves Rs m3,7613,443 109.2%   
Net worth Rs m4,0783,504 116.4%   
Long term debt Rs m1,671461 362.3%   
Total assets Rs m12,63313,755 91.8%  
Interest coverage x1.01.5 70.3%   
Debt to equity ratio x0.40.1 311.3%  
Sales to assets ratio x0.30.3 100.4%   
Return on assets %3.410.6 32.5%  
Return on equity %0.111.7 1.0%  
Return on capital %7.738.7 19.8%  
Exports to sales %22.920.9 109.6%   
Imports to sales %14.38.1 175.5%   
Exports (fob) Rs m964954 101.1%   
Imports (cif) Rs m602372 161.8%   
Fx inflow Rs m9641,203 80.1%   
Fx outflow Rs m607467 130.1%   
Net fx Rs m357736 48.5%   
CASH FLOW
From Operations Rs m1,3451,049 128.2%  
From Investments Rs m-2,256-54 4,216.1%  
From Financial Activity Rs m-1,200-1,011 118.6%  
Net Cashflow Rs m-2,111-20 10,714.2%  

Share Holding

Indian Promoters % 4.5 74.5 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 1.4 1.3 103.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 23.6 398.7%  
Shareholders   20,807 10,259 202.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS